02 Sep TUMAGNOSTIC – Dutch green light for Phase 1 clinical trial
We are glad to share that the Clinical Trial Application prepared by Convert Pharmaceuticals for the Phase 1 Clinical Trial of CP-506 (NCT04954599) has been approved by both the Competent Authorities and the reference Ethical Committee in the Netherlands. The prodrug will be tested in monotherapy setting as well as in combination with standard treatments such as immune checkpoint inhibitors or chemotherapy. Patient selection will be based upon key biomarkers.
The company now expects to finalise the same procedures in Belgium in the coming months and launch patient recruitment by the end of 2022.